drugset / Trial / NCT03885180
Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy
RandomizedParallel-groupOpen-labelPrevention
Summary
Guidelines recommended that patients with bioprosthetic heart valves (BHV) only need 6 months oral anticoagulation therapy after operation. However, a small part of patients still suffered thrombotic events after withdrawal of warfarin, which means these patients may need extend anticoagulation therapy. D-dimer, a sensitive marker of thrombosis or prethromboembolism state. Previous studies have demostrated that patients with elevated D-dimer levels have significant more clinical outcomes than those with nagative D-dimer levels. The aim of this study was to evaluate whether D-dimer could guide the duration of oral anticoagulation therapy in patients with BHV.
Timeline
- Start
- 2019-03-20
- Primary completion
- 2021-03-01
- Completion
- 2021-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Warfarin | Small molecule | — | Oral |